Press Release

July 29, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Subject: Press Release for Unaudited Financial Results for quarter ended June 30, 2026 Dear Sir/ Madam, In terms of regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations,2015, please find enclosed herewith a copy of Press Release along with Investor’s presentation for the Unaudited Financial results for the quarter ended June 30, 2026. We request you to take the above on record. Thanking you, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance officer Jagsonpal Pharmaceuticals Ltd announces Q1 FY27 Results Strong Start to FY27 Revenue up 9%, PAT up 22% and cash reserves at ₹1,700 Mn; Aequitas – Strong platform for foray into hospital business Gurugram, July 29, 2026: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) today announced the audited financial results for the quarter and year ended June 30, 2026. ₹ in Mn Q1FY27 Q4FY26 QoQ % Q1FY26 YoY% Revenue 822 642 28.1% 756 8.8% Operating EBITDA* 191 106 80.7% 157 21.4% EBITDA Margin* 23.2% 16.4% 675 bps 20.8% 241 bps PAT 132 88 50.5% 108 22.2% *Operating EBITDA and EBITDA margins before ESOP Q1FY27 Key Highlights:  Growing quarter across all Metrics: Revenue +9% YoY | Op. EBITDA +21% YoY | PBT +23% YOY | PAT +22% YoY, reflecting strong operating momentum  EBITDA indicating sustainable growth: Op. EBITDA rose to ₹191 Mn, driving margin expansion to 23.2% (+241 bps YoY), driven by operating leverage through improved MR productivity  Another quarter of higher profitability: PAT reached ₹132 Mn with margins expanding to 16.0%,  Growth delivered without compromising liquidity: Cash balance remained robust at ₹1,700 Mn despite a ₹400 Mn buyback, highlighting the strength of business model and disciplined execution  Capital deployed, financial strength retained: Completed Aequitas acquisition from internal accruals and yet maintaining a debt-light, cash-rich balance sheet  Value creation underway: Starting with Aequitas’s revenue base of ₹533 Mn, driving higher revenue and improved profitability from H2FY27; targeting of ₹100+ Mn EBITDA by Year 2 post-integration. Commenting on the performance for the quarter, Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals Limited said, “Q1FY27 reflects sustained traction in our business, with revenue growing 9% YoY, driven by higher MR productivity and continued strength across our key brands. We significantly outperformed the industry, with Pharmarack reporting 18.9% growth for Jagsonpal versus 11.6% for the IPM, leading to a 4 ranks improvement to #88 in the Indian pharmaceutical market. This translated into strong financial performance, with Op. EBITDA rising 21% YoY to ₹19 crore, Op. EBITDA margin expanding 241 bps to 23.2%, and PAT growing 22%. We recently completed the acquisition of a controlling stake (85%) in Aequitas Healthcare, marking our entry into the hospital supplies segment. We also concluded our ₹40 crore share buyback resulting in an ROCE improvement by 340 bps. Even with these capital allocation initiatives, we ended the quarter with a healthy cash balance of ₹170 crore. With a stronger business franchise, disciplined capital allocation, and multiple growth levers in place, we remain confident of sustaining profitable growth while pursuing value-accretive inorganic opportunities.” ABOUT JAGSONPAL PHARMACEUTICALS LIMITED Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over four decades in the Indian pharmaceutical market. The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, Dermatology and Child-care segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst Top 5 brands in the molecule category, extensive pan-India presence and an experienced sales team of ~1,000 professional sales representatives. The company is listed on the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789) and is headquartered in Delhi. For more information, please visit: www.jagsonpal.com Company contact Investor Relations Team Email: cs@jagsonpal.com, Soumya Chhajed Tel: +91 124 4406710 Email- soumya@goindiaadvisors.com Mobile: +91-8619707750 Jagsonpal Pharmaceuticals Limited CIN: L74899DL1978PLC009181 Registered Office: Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, , New Delhi, Delhi, 110020 Corporate Office: Nimai Tower, 3rd floor, Udyog Vihar, Gurugram, Haryana – 122015 Jagsonpal Pharmaceuticals Limited Q1FY27 Investor Presentation 29th July 2026 Safe Harbor This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and several risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations. These factors include, but not limited to: 1) change in the general market and macro-economic conditions, 2) governmental and regulatory trends, 3) successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 4) movements in currency exchange and interest rates, 5) increase in the competitive pressures and technological developments, 6) changes in the financial conditions of third parties dealing with us, 7) changes in laws and regulations that apply to our customers, suppliers and the pharmaceutical industry. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Jagsonpal Pharmaceuticals Limited may vary materially from those described in the relevant forward-looking statements. The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation because of new information, future events or otherwise. This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. Management Commentary "Q1FY27 reflects sustained traction in our business, with revenue growing 9% YoY, driven by higher MR productivity and growth across key brands. We significantly outperformed the industry, with Pharmarack reporting 18.9% growth for Jagsonpal versus 11.6% for the IPM, leading to a 4 ranks improvement to #88 in the Indian pharmaceutical market. This translated into strong financial performance, with Op. EBITDA rising 21% YoY to ₹19 crore, Op. EBITDA margin expanding 241 bps to 23.2%, and PAT growing 22%. We recently completed the acquisition of a controlling stake (85%) in Aequitas Healthcare, marking our entry into the hospital supplies business. We also concluded our ₹40 crore share buyback resulting in ROCE improvement by 340 bps. Even with these capital allocation initiatives, we [Showing first 8,000 characters — download PDF for full document]